Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Leist

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Neurology|June 11, 2003
Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1bS Markovic-Plese, B Bielekova, N Kadom, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 26, 2001
Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosisN D Richert, J L Ostuni, C N Bash, et al.
Multiple Sclerosis and Related Disorders|December 7, 2016
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysisMark S Freedman, Xavier Montalban, Aaron E Miller, et al.
Frontiers in Neurology|March 3, 2020
N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory StudyDaniel A Monti, George Zabrecky, Thomas P Leist, et al.
Current Medical Research and Opinion|September 14, 2006
A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosisLloyd H Kasper, Daniel Everitt, Thomas P Leist, et al.
Neurodegenerative Disease Management|January 12, 2022
Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summaryJiwon Oh, Bryan Walker, Gavin Giovannoni, et al.
Frontiers in Immunology|January 10, 2022
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine TabletsGavin Giovannoni, Patricia K Coyle, Patrick Vermersch, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 4, 2021
Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosisJiwon Oh, Bryan Walker, Gavin Giovannoni, et al.
Neurodegenerative Disease Management|August 26, 2022
Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summaryNicola De Stefano, Maria Pia Sormani, Gavin Giovannoni, et al.
Annals of Neurology|March 24, 2005
Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic diseaseUnsong Oh, Yoshihisa Yamano, Carlos A Mora, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Neurology|June 11, 2003
Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1bS Markovic-Plese, B Bielekova, N Kadom, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 26, 2001
Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosisN D Richert, J L Ostuni, C N Bash, et al.
Multiple Sclerosis and Related Disorders|December 7, 2016
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysisMark S Freedman, Xavier Montalban, Aaron E Miller, et al.
Frontiers in Neurology|March 3, 2020
N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory StudyDaniel A Monti, George Zabrecky, Thomas P Leist, et al.
Current Medical Research and Opinion|September 14, 2006
A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosisLloyd H Kasper, Daniel Everitt, Thomas P Leist, et al.
Neurodegenerative Disease Management|January 12, 2022
Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summaryJiwon Oh, Bryan Walker, Gavin Giovannoni, et al.
Frontiers in Immunology|January 10, 2022
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine TabletsGavin Giovannoni, Patricia K Coyle, Patrick Vermersch, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 4, 2021
Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosisJiwon Oh, Bryan Walker, Gavin Giovannoni, et al.
Neurodegenerative Disease Management|August 26, 2022
Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summaryNicola De Stefano, Maria Pia Sormani, Gavin Giovannoni, et al.
Annals of Neurology|March 24, 2005
Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic diseaseUnsong Oh, Yoshihisa Yamano, Carlos A Mora, et al.
Pageof 8